MetaCap

Lexicon Pharmaceuticals Insider Trades

NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.68-0.08 (-4.55%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
8 · $2.72M
Sales
0 · $0
Shares bought / sold
2.06M / 0
Net activity
Net buying $2.7 million

Lexicon Pharmaceuticals insider activity

Over the last 12 months, Lexicon Pharmaceuticals insiders reported 45 transactions on SEC Form 4: 8 open-market purchases and 0 sales. Insiders bought $2.7 million and sold $0 worth of stock, for net insider buying of $2.7 million. The most recent filing shows Swain Judith L (Director) reporting a transaction in 89,312 shares on Jun 3, 2026.

Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put LXRX's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

LXRX insider transactions

Lexicon Pharmaceuticals insider transactions
DateInsiderTypeSharesValueFiling
Jun 3, 2026Sullivan Diane E.DirectorOption exercise89,312—Form 4
Jun 3, 2026DEBBANE RAYMONDDirectorOption exercise89,312—Form 4
Jun 3, 2026Amouyal PhilippeDirectorOption exercise89,312—Form 4
Jun 3, 2026BARKER SAM LDirectorOption exercise89,312—Form 4
Jun 3, 2026Cheung IvanDirectorOption exercise89,312—Form 4
Jun 3, 2026SOBECKI CHRISTOPHER JDirectorOption exercise89,312—Form 4
Jun 3, 2026Swain Judith LDirectorOption exercise89,312—Form 4
Apr 30, 2026Artal Participations S.a r.l. & Artal International S.C.A. & Artal International Management S.A. & Artal Group S.A. & Westend S.A. & Stichting Administratiekantoor Westend & Wittouck AmauryDirectorOption exercise20,421,735—Form 4
Feb 28, 2026Exton MichaelChief Executive OfficerTax withholding204,831$301.10KForm 4
Feb 28, 2026Exton MichaelChief Executive OfficerOption exercise503,263—Form 4
Feb 28, 2026Granowitz Craig BSVP, Chief Medical OfficerTax withholding109,098$160.37KForm 4
Feb 28, 2026Granowitz Craig BSVP, Chief Medical OfficerOption exercise202,260—Form 4
Feb 28, 2026Granowitz Craig BSVP, Chief Medical OfficerOption exercise74,226—Form 4
Feb 28, 2026Granowitz Craig BSVP, Chief Medical OfficerOption exercise35,790—Form 4
Feb 28, 2026Coiante Scott MSVP, Chief Financial OfficerTax withholding54,881$80.68KForm 4
Feb 28, 2026Coiante Scott MSVP, Chief Financial OfficerOption exercise160,237—Form 4
Feb 28, 2026Crum Brian TSVP, General Counsel & Secr.Tax withholding105,019$154.38KForm 4
Feb 28, 2026Crum Brian TSVP, General Counsel & Secr.Option exercise170,163—Form 4
Feb 28, 2026Crum Brian TSVP, General Counsel & Secr.Option exercise69,386—Form 4
Feb 28, 2026Crum Brian TSVP, General Counsel & Secr.Option exercise33,457—Form 4
Feb 28, 2026DeFrancesco LisaSVP, IR and Corp CommTax withholding74,572$109.62KForm 4
Feb 28, 2026DeFrancesco LisaSVP, IR and Corp CommOption exercise128,190—Form 4
Feb 28, 2026DeFrancesco LisaSVP, IR and Corp CommOption exercise24,674—Form 4
Feb 28, 2026Gopinathan SumaSVP, DiscoveryTax withholding24,338$35.78KForm 4
Feb 28, 2026Gopinathan SumaSVP, DiscoveryOption exercise65,640—Form 4
Feb 28, 2026Gopinathan SumaSVP, DiscoveryOption exercise20,310—Form 4
Feb 28, 2026Gopinathan SumaSVP, DiscoveryOption exercise14,000—Form 4
Feb 28, 2026Martens Rachel YapSVP, Partnerships & Corp StratTax withholding35,826$52.66KForm 4
Feb 28, 2026Martens Rachel YapSVP, Partnerships & Corp StratOption exercise67,090—Form 4
Feb 28, 2026McDermott WendySVP, Human ResourcesTax withholding68,107$100.12KForm 4
Feb 28, 2026McDermott WendySVP, Human ResourcesOption exercise144,393—Form 4
Feb 28, 2026McDermott WendySVP, Human ResourcesOption exercise52,316—Form 4
Feb 28, 2026McDermott WendySVP, Human ResourcesOption exercise27,697—Form 4
Feb 25, 2026DEBBANE RAYMONDDirectorBuy2,000$2.98KForm 4
Feb 23, 2026DEBBANE RAYMONDDirectorBuy100,000$147.00KForm 4
Feb 20, 2026DEBBANE RAYMONDDirectorBuy100,000$147.79KForm 4
Feb 19, 2026DEBBANE RAYMONDDirectorBuy50,000$71.97KForm 4
Feb 18, 2026DEBBANE RAYMONDDirectorBuy133,688$176.47KForm 4
Feb 17, 2026DEBBANE RAYMONDDirectorBuy76,857$100.54KForm 4
Feb 17, 2026Artal Participations S.a r.l. & Artal International S.C.A. & Artal International Management S.A. & Artal Group S.A. & Westend S.A. & Stichting Administratiekantoor Westend & Wittouck AmauryDirectorAward41,290$2.68MForm 4
Feb 13, 2026DEBBANE RAYMONDDirectorBuy57,952$75.88KForm 4
Feb 2, 2026Invus Global Management, LLC & Siren, L.L.C. & DEBBANE RAYMOND & Artal Participations S.a r.l. & Artal International S.C.A. & Artal International Management S.A. & Artal Group S.A. & Westend S.A. & Stichting Administratiekantoor WestendDirectorAward367,145$23.86MForm 4
Feb 2, 2026Invus Global Management, LLC & Siren, L.L.C. & DEBBANE RAYMOND & Artal Participations S.a r.l. & Artal International S.C.A. & Artal International Management S.A. & Artal Group S.A. & Westend S.A. & Stichting Administratiekantoor WestendDirectorBuy1,538,462$2.00MForm 4
Feb 2, 2026Invus Global Management, LLC & Siren, L.L.C. & DEBBANE RAYMOND & Artal Participations S.a r.l. & Artal International S.C.A. & Artal International Management S.A. & Artal Group S.A. & Westend S.A. & Stichting Administratiekantoor WestendDirectorAward3,846,154$5.00MForm 4
Feb 2, 2026Invus Global Management, LLC & Siren, L.L.C. & DEBBANE RAYMOND & Artal Participations S.a r.l. & Artal International S.C.A. & Artal International Management S.A. & Artal Group S.A. & Westend S.A. & Stichting Administratiekantoor WestendDirectorAward18,553,846$24.12MForm 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related